Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
n this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-tShort Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report...
Feature article: 2022 Pharma Statistics - 8.7% growth – but worrying signs An efficient reporting system has seen all the listed multinational pharmaceutical companies announcing results for 2022, which has given us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of the global and US rankings of the top 20 drug companies for 2022. 2022 was characterised by 8.7% underlying growth, offset by a large forex impact (-12%), due to USD stren...
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
The general evaluation of JAZZ PHARMACEUTICALS (US), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 3 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date December 31, 2021, the closing pr...
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Jazz Pharmaceuticals found large success with narcolepsy treatment Xyrem and is now transforming into a diversified orphan-focused pharmaceutical firm for life after Xyrem. While the firm still has a way to go, its Exemplary stewardship and successful execution of Xyrem's tricky pricing situation give us confidence in its ability to execute. However, given the uncertainty around the entry of Xyrem generics and Jazz’s lack of diversification in its current portfolio, we believe there is a risk ...
We are maintaining our $153 fair value estimate for no-moat Jazz following the company's first-quarter results, which were mostly in line with our expectations. Total revenue of $508 million met our expectations and represents 14% growth from last year and 7% sequentially. Research and development spend was slightly below our expectations, but we don't plan to change our full-year outlook, as clinical trial costs may ramp up in the back half of the year. Lead therapy Xyrem for narcolepsy contrib...
We are maintaining our $153 fair value estimate for no-moat Jazz following the company's first-quarter results, which were mostly in line with our expectations. Total revenue of $508 million met our expectations and represents 14% growth from last year and 7% sequentially. Research and development spend was slightly below our expectations, but we don't plan to change our full-year outlook, as clinical trial costs may ramp up in the back half of the year. Lead therapy Xyrem for narcolepsy contri...
We are maintaining our $153 fair value estimate for no-moat Jazz following the company's first-quarter results, which were mostly in line with our expectations. Total revenue of $508 million met our expectations and represents 14% growth from last year and 7% sequentially. Research and development spend was slightly below our expectations, but we don't plan to change our full-year outlook, as clinical trial costs may ramp up in the back half of the year. Lead therapy Xyrem for narcolepsy contrib...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.